RCT: Effect of Apatinib plus Pegylated Liposomal Doxorubicin vs. Pegylated Liposomal Doxorubicin alone on platinum-resistant recurrent ovarian cancer. 1 Jul, 2022 | 10:37h | UTC Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial – JAMA Oncology See also: Visual Abstract